Stock 5CV CUREVAC N.V.
Add to a list
To use this feature you must be a member
Log inSign up

CureVac N.V. Share Price Deutsche Boerse AG

Equities

5CV

NL0015436031

Biotechnology & Medical Research

Real-time Estimate Tradegate
Other stock markets
 06:48:53 17/06/2024 pm IST 		5-day change 1st Jan Change
3.375 EUR -0.85% Intraday chart for CureVac N.V. -20.29% -12.81%
28/05 CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate MT
28/05 CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK CI

Financials

Sales 2024 * 5.66Cr 6.07Cr 506.5Cr Sales 2025 * 8.64Cr 9.26Cr 773.36Cr Capitalization 77Cr 82Cr 6.89TCr
Net income 2024 * -21Cr -23Cr -1.89TCr Net income 2025 * -13Cr -14Cr -1.16TCr EV / Sales 2024 * 12.1 x
Net cash position 2024 * 8.64Cr 9.25Cr 772.62Cr Net cash position 2025 * 18Cr 20Cr 1.65TCr EV / Sales 2025 * 6.77 x
P/E ratio 2024 *
-3.57 x
P/E ratio 2025 *
-6.4 x
Employees 1,086
Yield 2024 *
-
Yield 2025 *
-
Free-Float 54.73%
More Fundamentals * Assessed data

Chart CureVac N.V.

Dynamic Chart

Latest news about CureVac N.V.

CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate MT
CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK CI
CureVac N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
CUREVAC : Significant cash drain in the Q1 Alphavalue
Health Care Up as Vaccine Makers Gain - Health Care Roundup DJ
CUREVAC : A missed opportunity Alphavalue
UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating MT
Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4 MT
CureVac N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
CureVac Begins Early Stage Portion of Investigational Vaccine Trial MT
CureVac Hires New Chief Business Officer MT
CureVac, GSK Launch Phase 1/2 Trial of Bird Flu Vaccine Candidate MT
Transcript : CureVac N.V., Q4 2023 Earnings Call, Apr 24, 2024
Earnings Flash (CVAC) CUREVAC Posts Q4 Revenue EUR22.6M MT
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer, Effective June 1, 2024 CI
More news

Latest transcript on CureVac N.V.

Logo CureVac N.V.
CureVac N.V., Q4 2023 Earnings Call, Apr 24, 2024
More transcripts

Analyst Recommendations on CureVac N.V.

CUREVAC : Significant cash drain in the Q1 Alphavalue
CUREVAC : A missed opportunity Alphavalue
UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating MT
Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4 MT
Kempen Upgrades CureVac to Buy From Neutral, Price Target is $10 MT
More recommendations

Press releases CureVac N.V.

CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza, Development in Collaboration with GSK AQ
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK EQ
CureVac N : Proxycard AGM 2024 PU
CureVac N : Dutch Statutory Board Report and Financial Statements of CureVac N.V. 2023 PU
CureVac N : Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) - Form 6-K PU
More press releases

News in other languages on CureVac N.V.

Öl- und Bankentitel schwach - EZB wirft Schatten voraus
XETRA-SCHLUSS/DAX schwächer - der Bund macht Kasse
CureVac gibt Impfung des ersten Teilnehmers in einer Phase-2-Studie zur saisonalen Grippe bekannt; Entwicklung in Zusammenarbeit mit GSK
CureVac gibt Impfung des ersten Teilnehmers in einer Phase-2-Studie zur saisonalen Grippe bekannt; Entwicklung in Zusammenarbeit mit GSK
Starke Einkaufsmanager verderben Nvidia-Laune
More news

Quotes and Performance

1 day-0.85%
1 week-20.29%
Current month-6.48%
1 month+5.08%
3 months+14.07%
6 months-35.37%
Current year-12.81%
More quotes

Highs and lows

1 week
3.35
Extreme 3.348
4.25
1 month
3.00
Extreme 3
4.81
Current year
2.06
Extreme 2.056
4.81
1 year
2.06
Extreme 2.056
11.20
3 years
2.06
Extreme 2.056
64.40
5 years
2.06
Extreme 2.056
125.44
10 years
2.06
Extreme 2.056
125.44
More quotes

Managers and Directors - CureVac N.V.

Managers TitleAgeSince
Alexander Zehnder CEO
 Chief Executive Officer 54 28/23/28
Pierre Kemula DFI
 Director of Finance/CFO 50 01/16/01
Malte Greune COO
 Chief Operating Officer 59 01/21/01
Members of the board TitleAgeSince
Craig Tooman BRD
 Director/Board Member 58 01/19/01
Michael Brosnan BRD
 Director/Board Member 69 19/23/19
Klaus Schollmeier BRD
 Director/Board Member 67 22/22/22
More insiders

Quotes

Date Price Change Volume
17/24/17 3.348 -1.65% 5 902
14/24/14 3.404 -8.94% 41,033
13/24/13 3.738 -4.15% 9,777
12/24/12 3.9 -1.71% 20,062
11/24/11 3.968 -5.52% 15,720

Delayed Quote Deutsche Boerse AG, June 17, 2024 at 05:10 pm IST

More quotes

Company Profile

CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve people’s lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.
Sector
Biotechnology & Medical Research
Calendar
15/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for CureVac N.V.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
3.431 EUR
Average target price
8.728 EUR
Spread / Average Target
+154.38%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+40.80% 5.37TCr
LONZA GROUP AG Stock Lonza Group AG
+34.49% 3.89TCr
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.05% 3.88TCr
CELLTRION, INC. Stock Celltrion, Inc.
-8.98% 2.73TCr
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.69% 2.59TCr
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-16.21% 2.03TCr
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+31.00% 1.28TCr
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.51% 1.22TCr
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-1.67% 1.2TCr
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CVAC Stock
  4. 5CV Stock